Tech Guide 2018 on Prostate cancer imaging and therapy - Chapter 8

This track provides a comprehensive and evidence-based overview of the current state of radionuclide therapy based on alpha emitters for prostate cancer. After a short introduction about the main epidemiological and clinical features of skeletal metastases from prostate cancer, the properties of alpha-particles and the “historical” radiopharmaceuticals used in this field; the core of this lecture focuses on radionuclide therapy based on radium-223. The radium-223 therapy will be discussed in terms of physical, biological and clinical properties showing some specially selected interactive cases that will help to understand better the theoretical issues. The last part of the track include a short view of new possible radiopharmaceuticals with therapeutic action in prostate cancer.

User action required
If you have the permission to view this publication, please log in.